Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Pedro M MachadoSaskia Lawson-ToveyAnja StrangfeldElsa F MateusKimmie L HyrichLaure GossecLoreto CarmonaAna RodriguesNicolas RouxCatia DuarteEric HachullaEric VeillardEva StrakovaGerd-Rüdiger R BurmesterGözde Kübra YardımcıJosé A Gómez-PuertaJulija ZepaLianne Kearsley-FleetLudovic TrefondMaria CunhaMarta MoscaMartina CornalbaMartin SoubrierNicolas RouxOlivier BrocqPatrick DurezRichard P ConwayTiphaine GoulenokJohannes W J BijlsmaIain B McInnesXavier MariettePublished in: Annals of the rheumatic diseases (2021)
The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.